Live Analyst Rating Changes 1941 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Dane Leone
RJ
Dane Leone
Wall Street Analyst
★★☆☆☆
#1940
on 13Foresight · ranked by our own returns
53%
Success Rate
+32.1%
Average Return
19 of 36 calls profitable · -21.4% vs benchmark
📈 Across the calls we could measure, roughly 53% of Dane Leone's ratings turned a profit when each position was held for 1 year — averaging +32.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

1 Buy 1 Hold 0 Sell
Dane's Stock Coverage 38 ratings · 2026-06-23
Company Date Position Consensus Price Target 1-Yr Return
BMY
Bristol-Myers Squibb
Oct 13, 2025 HOLD Buy
+8.2% avg upside
42 analysts
+26.8%
OCUL
Ocular Therapeutix
Aug 04, 2025 BUY Strong Buy
+149.9% avg upside
21 analysts
$19.00
101.52% Upside
-19.3%
CYTK
Cytokinetics
Apr 02, 2025 BUY Strong Buy
+8.2% avg upside
36 analysts
$81.00
2.81% Upside
+65.8%
RVMD
Revolution Medicines
Nov 15, 2023 BUY Strong Buy
-13.2% avg upside
32 analysts
$30.00
81.52% Downside
+158.3%
REGN
Regeneron
Nov 02, 2023 BUY Strong Buy
+26.8% avg upside
57 analysts
$950.00
55.78% Upside
+3.0%
NKTX
Nkarta
Oct 17, 2023 BUY Strong Buy
+561.5% avg upside
15 analysts
$13.00
354.49% Upside
+27.4%
BBIO
BridgeBio Pharma
Jul 18, 2023 BUY Strong Buy
+35.5% avg upside
34 analysts
$46.00
30.51% Downside
-20.3%
LKFT
Lakefront Biotherapeutics
May 05, 2023 BUY Hold
+266.6% avg upside
24 analysts
$69.00
143.74% Upside
·
RGNX
RegenXBio
May 03, 2023 BUY Strong Buy
+341.8% avg upside
22 analysts
$65.00
733.34% Upside
-16.8%
RLAY
Relay Therapeutics
Apr 19, 2023 BUY Strong Buy
+20.8% avg upside
19 analysts
$29.00
82.71% Upside
-51.7%
AMGN
Amgen
Apr 17, 2023 HOLD Buy
-12.8% avg upside
57 analysts
+10.0%
SLP
Simulations Plus
Apr 05, 2023 BUY Buy
+90.5% avg upside
11 analysts
$70.00
283.86% Upside
+14.7%
LIANY
LianBio Sponsored ADR
Mar 28, 2023 BUY Buy
+11065.9% avg upside
4 analysts
$15.00
13462.39% Upside
·
ALLO
Allogene Therapeutics
Feb 28, 2023 HOLD Strong Buy
+634.9% avg upside
28 analysts
-19.4%
CMPX
Compass Therapeutics
Jan 20, 2023 BUY Strong Buy
+363.0% avg upside
19 analysts
+1097.8%
XLO
Xilio Therapeutics
Dec 01, 2022 BUY Strong Buy
+93.2% avg upside
7 analysts
$13.00
47.83% Upside
-56.5%
XNCR
Xencor
Nov 08, 2022 BUY Strong Buy
+144.9% avg upside
27 analysts
$58.00
358.81% Upside
-41.2%
CRIS
Curis
Apr 04, 2022 HOLD Strong Buy
+1957.4% avg upside
12 analysts
-64.2%
VYGR
Voyager Therapeutics
Mar 22, 2022 HOLD Strong Buy
+283.4% avg upside
23 analysts
-13.3%
TARS
Tarsus Pharmaceuticals
Oct 07, 2021 BUY Strong Buy
+19.8% avg upside
16 analysts
$65.00
2.94% Upside
-24.6%
DNLI
Denali Therapeutics
Jul 25, 2021 HOLD Strong Buy
+57.0% avg upside
24 analysts
-34.7%
LCTX
Lineage Therap
Mar 11, 2021 HOLD Strong Buy
+334.2% avg upside
16 analysts
-42.7%
DNTH
Dianthus Therapeutics
Jun 11, 2020 BUY Strong Buy
+3.4% avg upside
29 analysts
$15.00
81.82% Downside
+28.1%
MGNX
MacroGenics
Sep 10, 2018 BUY Buy
+297.0% avg upside
25 analysts
$30.00
626.42% Upside
-32.2%
JNJ
Johnson & Johnson
May 21, 2018 SELL Strong Buy
-4.4% avg upside
36 analysts
$110.00
51.93% Downside
-14.7%
VRTX
Vertex Pharmaceuticals
Apr 26, 2018 BUY Strong Buy
-4.8% avg upside
61 analysts
$200.00
55.71% Downside
+8.8%
CRVS
Corvus Pharmaceuticals
Nov 13, 2017 BUY Strong Buy
+108.8% avg upside
14 analysts
$26.00
118.21% Upside
-41.1%
ABT
Abbott Laboratories
Jun 21, 2017 BUY Strong Buy
+31.8% avg upside
35 analysts
$56.00
36.58% Downside
+29.7%
ILMN
Illumina
Mar 16, 2017 HOLD Buy
-9.9% avg upside
30 analysts
+59.2%
DHR
Danaher
Sep 06, 2016 BUY Strong Buy
+21.4% avg upside
45 analysts
$92.00
48.16% Downside
+6.4%
TMO
Thermo Fisher
May 27, 2016 HOLD Strong Buy
+26.9% avg upside
38 analysts
+14.4%
A
Agilent
May 24, 2016 BUY Strong Buy
+4.0% avg upside
32 analysts
$50.00
60.63% Downside
+32.9%
BRKR
Bruker
May 05, 2016 HOLD Buy
-6.5% avg upside
22 analysts
$28.00
50.98% Downside
-3.8%
RVTY
Revvity
Feb 04, 2016 HOLD Buy
+5.8% avg upside
23 analysts
+12.6%
MYGN
Myriad Genetics
Jun 05, 2014 HOLD Hold
+315.1% avg upside
24 analysts
$36.00
692.88% Upside
-5.6%
SUN
Sunoco
May 08, 2014 HOLD Strong Buy
+2.4% avg upside
12 analysts
$40.00
37.10% Downside
+21.1%
CASY
Casey's General
Feb 21, 2014 HOLD Strong Buy
-23.5% avg upside
27 analysts
$70.00
91.78% Downside
+37.9%
DGX
Quest Diagnostics
Jul 19, 2013 BUY Buy
-12.1% avg upside
33 analysts
+4.2%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Dane Leone — Frequently Asked Questions
How accurate are Dane Leone's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Dane's ratings were profitable over a one-year hold, with an average return of +32.1% per rating, or -21.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Dane ranked on 13Foresight?
Dane Leone is currently ranked #1940 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Dane cover?
Dane most recently has ratings on BMY, OCUL, CYTK, RVMD, REGN, NKTX, BBIO, LKFT, RGNX, RLAY, AMGN, SLP and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.